The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
about
Tuberculosis vaccines: beyond bacille Calmette-GuerinAdvances and hurdles on the way toward a leprosy vaccine.Treating BCG-induced disease in childrenTreatments for BCG-induced disease in childrenNonpathogenic SIV and Pathogenic HIV Infections Associate with Disparate Innate Cytokine Signatures in Response to Mycobacterium bovis BCGApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyRecent advances towards tuberculosis control: vaccines and biomarkersVaccines against tuberculosis: where are we and where do we need to go?Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gapsPrime-boost approaches to tuberculosis vaccine developmentSimultaneous immunization against tuberculosisPaediatric tuberculosis.Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy.HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine.Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.Exosomes carrying mycobacterial antigens can protect mice against Mycobacterium tuberculosis infection.BCG vaccination in South African HIV-exposed infants--risks and benefitsApplication of nanotechnologies for improved immune response against infectious diseases in the developing worldCD4 and CD8 T-cell responses to mycobacterial antigens in African childrenPreventing infective complications in inflammatory bowel disease.Tuberculosis in children.The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in miceA novel vaccine p846 encoding Rv3615c, Mtb10.4, and Rv2660c elicits robust immune response and alleviates lung injury induced by Mycobacterium infection.HIV-Associated Tuberculosis in the Newborn and Young Infant.The tuberculosis vaccine candidate Bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in miceVaccine against tuberculosis: what's new?Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate.Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in childrenA recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.DNA-Launched Alphavirus Replicons Encoding a Fusion of Mycobacterial Antigens Acr and Ag85B Are Immunogenic and Protective in a Murine Model of TB Infection.Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsFormulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis.BCG Vaccination in HIV-Infected Children.Challenges of Childhood TB/HIV Management in Malawi.A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaquesEfficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primatesRobust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaquesDiagnostic and management challenges for childhood tuberculosis in the era of HIV.
P2860
Q22242669-B55A2C9E-0A0D-40EF-8014-18E7400794B3Q22305432-19F02E6C-411D-43F1-8785-B0630554684CQ24201807-FE22332D-84EE-4B59-91B3-DBD1FFFE5FABQ24239915-C78A4EC0-44BF-4574-BAF2-19EF8BDBCAD2Q26779512-C75C7A60-9A68-49C0-B90D-736E54CC8EC1Q26798372-146D58A7-3A06-482F-B022-487B4C683660Q26859739-B723C69C-3236-4C91-AEC7-9548968731BCQ26992233-DEE4BFBD-6ECA-447C-9B45-8F47BC356EEAQ27022592-EC3B07F0-9B8B-4072-B259-22DBB52A233AQ27024526-B18BC931-81E6-4FE9-A4A3-935BF343D605Q28742666-7798FA42-BEEC-4BCD-AC8F-786D8F91D458Q33581724-A9F6496A-6EEA-4436-B441-8FB56F1852EAQ33584559-46864B3F-7708-4EF7-AB21-E8DB7BDBD058Q33605245-4F131B00-F8D6-4BA9-876D-12683AF8C91AQ33627000-6318A495-5903-40FB-ABFD-6B068799D88CQ33804506-DB24D292-F287-4D71-A1CC-16688DCF43FBQ33827831-642F6E1D-9CED-4AAB-A00B-119F09FF4435Q33848471-6598F83A-0D6F-4074-AD1C-ED4FAADB40BDQ33894321-DEA7A751-01EA-4764-B0A3-1D2BD611056EQ33988111-1A6D3122-1FE4-4B4A-B207-5DC735F60419Q34008766-B84771E7-666F-4E2E-A4BD-DAFEEAAC94AAQ34083196-785565FE-41E6-416B-9770-D567E14EEB53Q34261521-0F69AA8C-7E57-4038-B35F-A004BC93FAC7Q34290745-5F0D5B48-D139-477C-9E69-4FB45D145DF8Q34877096-1FD0FA9E-0D1A-4AC6-ACA3-7ED9F4889C7BQ35043659-FC342EE1-00C8-4147-B4D0-AB00F1C38296Q35101472-84B0168F-33F1-4B54-BB84-080E03943670Q35301384-5A03D139-8F48-4FCB-AA8D-6611851FD2B9Q35530277-D9B0DDD9-50F9-467E-9D42-38840CD4BB5AQ35647253-45FF9C9C-DCB4-47CD-BE79-6C5682851878Q35758746-BB616688-19F8-4903-95E2-9E732023CBE1Q35826779-D1FC369D-67BE-4A0F-90CA-BDD525A433B8Q35839810-4F5547B0-CAA9-4742-88FD-06B70C2D1822Q35910127-7825121E-6257-4E0D-9BEE-27311BDA569FQ35939235-F1E0534A-2C92-4814-A141-FAB85938376CQ36154750-A6B3276C-9874-4DB1-A199-DF717FD77FC0Q36439961-D3604A14-4C78-48C0-A12E-92067C023A2AQ36759963-A36EE77B-FB7F-4537-83FE-7A6E3D3D4FA4Q36826315-83BEE00A-4BEF-4C5F-8740-5E4317CE602CQ36877242-9217B35E-5954-4488-94B2-E58DE58FA5C2
P2860
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
@en
The risk of disseminated Bacille Calmette-Guerin
@nl
type
label
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
@en
The risk of disseminated Bacille Calmette-Guerin
@nl
prefLabel
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
@en
The risk of disseminated Bacille Calmette-Guerin
@nl
P2093
P1433
P1476
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
@en
P2093
Anneke C Hesseling
Ben J Marais
H Simon Schaaf
Paul E M Fine
Robert P Gie
P356
10.1016/J.VACCINE.2006.07.020
P407
P577
2006-08-01T00:00:00Z